ProKidney Corp. Q3 2025 Overview
WINSTON-SALEM, N.C. — ProKidney Corp. (Nasdaq: PROK), a leading clinical-stage cell therapy company dedicated to addressing chronic kidney disease (CKD), recently unveiled its financial performance for Q3 2025 while sharing insightful updates on regulatory and clinical advancements.
The third quarter showcased significant milestones, reflecting ProKidney's commitment to innovation and the potential of its flagship treatment, rilparencel.
Recent Clinical Developments
In a recent presentation at the American Society of Nephrology (ASN) Kidney Week 2025, ProKidney shared full results from the Phase 2 REGEN-007 study. This clinical trial primarily assessed the efficacy of rilparencel among patients suffering from advanced CKD and diabetes. A notable highlight was the substantial improvement of 4.6 mL/min/1.73m² in the annual decline in estimated glomerular filtration rate (eGFR) slope, marking a statistically significant outcome that reinforces the therapy's potential.
Furthermore, an impressive 63% of participants from the trial's Group 1 met the inclusion criteria for the following Phase 3 PROACT 1 study. This substantiates rilparencel's potential for serving as a novel treatment for advanced CKD and diabetes patients, who are at an elevated risk of kidney failure.
Continued Focus on Phase 3 Clinical Trials
ProKidney is eager to push forward with the ongoing Phase 3 PROACT 1 trial, which aims to accelerate the approval process for rilparencel. The trial’s design now benefits from the FDA's validation of using eGFR slope as a primary endpoint. With over half the targeted patient enrollment of approximately 360 completed, ProKidney anticipates topline results to be reported in Q2 2027, furthering the ambition of delivering this new therapy to those most in need.
Financial Performance Highlights
During the period ending in September 2025, ProKidney reported a robust liquidity position with $272 million in cash, cash equivalents, and marketable securities. This financial cushion supports operational needs into the middle of 2027, ensuring that ProKidney can continue its innovative research without interruption.
Research and development expenditures totaled $26.8 million for the quarter, showcasing a decrease compared to the previous year. This decline was largely due to the conclusion of other clinical trials, allowing the Company to focus its resources efficiently. Additionally, general and administrative expenses significantly fell to $11.9 million, primarily from reduced non-cash impairment charges.
Understanding CKD and ProKidney's Role
Chronic kidney disease is characterized by a progressive decline in kidney function, often leading to end-stage kidney failure. Currently, an estimated 37 million adults in the U.S. face this condition, with many remaining undiagnosed. Diabetes is notably the leading contributor to CKD, creating a pressing need for effective treatments that can mitigate or stall the disease's progression. ProKidney's rilparencel aims to provide a vital solution for those battling Stage 3b/4 CKD.
The Future of ProKidney
As ProKidney forges ahead with rilparencel, the Company remains dedicated to its mission of transforming CKD treatment options. Recent clinical findings and sound financial backing position ProKidney favorably as it approaches critical milestones in the regulatory process. As awareness grows around CKD and its accompanying risks, ProKidney continues to innovate, striving for a future where advanced therapies can stabilize kidney function and improve the quality of life for millions.
Frequently Asked Questions
What is ProKidney focused on?
ProKidney is focused on developing innovative treatments for chronic kidney disease (CKD) through its lead therapy, rilparencel.
What were ProKidney's financial results for Q3 2025?
ProKidney reported $272 million in cash and equivalents and a net loss of $35.8 million for Q3 2025.
What are the main findings from the Phase 2 REGEN-007 study?
The study revealed a significant 4.6 mL/min/1.73m² improvement in the annual decline in eGFR slope among treated patients.
When can we expect the results from the PROACT 1 study?
Topline results from the PROACT 1 study are anticipated in Q2 2027.
How does CKD affect the U.S. population?
An estimated 37 million adults in the U.S. have CKD, with many individuals undiagnosed and facing increased health risks.
